Skip to main content
Top
Published in: Journal of General Internal Medicine 8/2013

01-08-2013 | Original Research

Changing Interactions Between Physician Trainees and the Pharmaceutical Industry: A National Survey

Authors: Kirsten E. Austad, BS, Jerry Avorn, MD, Jessica M. Franklin, PhD, Mary K. Kowal, BA, Eric G. Campbell, PhD, Aaron S. Kesselheim, MD, JD, MPH

Published in: Journal of General Internal Medicine | Issue 8/2013

Login to get access

ABSTRACT

BACKGROUND

Increasingly, medical school policies limit pharmaceutical representatives’ access to students and gifts from drugmakers, but little is known about how these policies affect student attitudes toward industry.

OBJECTIVE

To assess interactions between trainees and the pharmaceutical industry, and to determine whether learning environment characteristics influence students’ practices and attitudes.

DESIGN, PARTICIPANTS

We conducted a cross-sectional survey with a nationally-representative sample of first- and fourth-year medical students and third-year residents, stratified by medical school, including ≥ 14 randomly selected trainees at each level per school.

MAIN MEASURES

We measured frequency of industry interactions and attitudes regarding how such interactions affect medical training and the profession. Chi-squared tests assessed bivariate linear trend, and hierarchical logistic regression models were fitted to assess associations between trainees’ attitudes and their schools’ National Institutes of Health (NIH) funding levels and American Medical Student Association (AMSA) PharmFree Scorecard grades reflecting industry-related conflict of interest policies.

KEY RESULTS

Among 1,610 student (49.3 % response rate) and 739 resident (43.1 %) respondents, industry-sponsored gifts were common, rising from 33.0 % (first-year students) to 56.8 % (fourth-year students) and 54 % (residents) (p < 0.001). These gifts included meals outside the hospital (reported by 5 % first-year students, 13.4 % fourth-year students, 27.5 % residents (p < 0.001)) and free drug samples (reported by 7.4 % first-year students, 14.1 % fourth-year students, 14.3 % residents (p < 0.001)). The perception that industry interactions lead to bias was prevalent, but the belief that physicians receive valuable education through these interactions increased (64.1 % to 67.5 % to 79.8 %, p < 0.001). Students in schools receiving more NIH funding reported industry gifts less often (OR = 0.51, 95 % CI: 0.38–0.68, p < 0.001), but the strength of institutional conflict of interest policies was not associated with this variable.

CONCLUSIONS

Despite recent policy changes, a substantial number of trainees continue to receive gifts from pharmaceutical representatives. We found no relation between these outcomes and a school’s policies concerning interactions with industry.
Appendix
Available only for authorised users
Literature
1.
go back to reference Brody H. Pharmaceutical industry financial support for medical education: benefit, or undue influence? J Law Med Ethics. 2009;37(3):451–460.PubMedCrossRef Brody H. Pharmaceutical industry financial support for medical education: benefit, or undue influence? J Law Med Ethics. 2009;37(3):451–460.PubMedCrossRef
2.
go back to reference Campbell EG, Regan S, Gruen RL, Ferris TG, Rao SR, Cleary PD, Blumenthal D. Professionalism in medicine: results of a national survey of physicians. Ann Intern Med. 2007;147(11):795–802.PubMedCrossRef Campbell EG, Regan S, Gruen RL, Ferris TG, Rao SR, Cleary PD, Blumenthal D. Professionalism in medicine: results of a national survey of physicians. Ann Intern Med. 2007;147(11):795–802.PubMedCrossRef
3.
go back to reference Steinbrook R. Future directions in industry funding of continuing medical education. Arch Intern Med. 2011;171(3):257–258.PubMedCrossRef Steinbrook R. Future directions in industry funding of continuing medical education. Arch Intern Med. 2011;171(3):257–258.PubMedCrossRef
4.
go back to reference Avorn J, Choudhry NK. Funding for medical education: maintaining a healthy separation from industry. Circulation. 2010;121(20):2228–2234.PubMedCrossRef Avorn J, Choudhry NK. Funding for medical education: maintaining a healthy separation from industry. Circulation. 2010;121(20):2228–2234.PubMedCrossRef
5.
go back to reference Campbell EG, Weissman JS, Ehringhaus S, Rao SR, Moy B, Feibelmann S, Goold SD. Institutional academic industry relationships. JAMA. 2007;298(15):1779–1786.PubMedCrossRef Campbell EG, Weissman JS, Ehringhaus S, Rao SR, Moy B, Feibelmann S, Goold SD. Institutional academic industry relationships. JAMA. 2007;298(15):1779–1786.PubMedCrossRef
6.
go back to reference Zipkin DA, Steinman MA. Interactions between pharmaceutical representatives and doctors in training. A thematic review. J Gen Intern Med. 2005;20(8):777–786.PubMedCrossRef Zipkin DA, Steinman MA. Interactions between pharmaceutical representatives and doctors in training. A thematic review. J Gen Intern Med. 2005;20(8):777–786.PubMedCrossRef
7.
go back to reference Fitz M, Homna D, Reddy S, Griffith C, Baker E, et al. The hidden curriculum: medical students’ changing opinions toward the pharmaceutical industry. Acad Med. 2007;82:S1–S3.PubMedCrossRef Fitz M, Homna D, Reddy S, Griffith C, Baker E, et al. The hidden curriculum: medical students’ changing opinions toward the pharmaceutical industry. Acad Med. 2007;82:S1–S3.PubMedCrossRef
8.
go back to reference Bellin M, McCarthy S, Drevlow L, Pierach C. Medical students’ exposure to pharmaceutical industry marketing: a survey at one U.S. medical school. Acad Med. 2004;79:1041–1045.PubMedCrossRef Bellin M, McCarthy S, Drevlow L, Pierach C. Medical students’ exposure to pharmaceutical industry marketing: a survey at one U.S. medical school. Acad Med. 2004;79:1041–1045.PubMedCrossRef
9.
go back to reference Hyman P, Hochman M, Shaw J, Steinman M. Attitudes of preclinical and clinical medical students toward interactions with the pharmaceutical industry. Acad Med. 2007;82:94–99.PubMedCrossRef Hyman P, Hochman M, Shaw J, Steinman M. Attitudes of preclinical and clinical medical students toward interactions with the pharmaceutical industry. Acad Med. 2007;82:94–99.PubMedCrossRef
11.
go back to reference Sierles FS, Brodkey AC, Cleary LM, McCurdy FA, Mintz M, Frank J, Lynn DJ, Chao J, Morgenstern BZ, Shore W, Woodard JL. Medical students’ exposure to and attitudes about drug company interactions: a national survey. JAMA. 2005;294(9):1034–1042.PubMedCrossRef Sierles FS, Brodkey AC, Cleary LM, McCurdy FA, Mintz M, Frank J, Lynn DJ, Chao J, Morgenstern BZ, Shore W, Woodard JL. Medical students’ exposure to and attitudes about drug company interactions: a national survey. JAMA. 2005;294(9):1034–1042.PubMedCrossRef
12.
go back to reference Soyk C, Pfefferkorn B, McBride P, Rieselbach R. Medical student exposure to and attitudes about pharmaceutical companies. WMJ. 2010;109(3):142–148.PubMed Soyk C, Pfefferkorn B, McBride P, Rieselbach R. Medical student exposure to and attitudes about pharmaceutical companies. WMJ. 2010;109(3):142–148.PubMed
13.
go back to reference Austad KE, Avorn J, Kesselheim AS. Medical students’ exposure to and attitudes about the pharmaceutical industry: a systematic review. PLoS Med. 2011;8(5):e1001037.PubMedCrossRef Austad KE, Avorn J, Kesselheim AS. Medical students’ exposure to and attitudes about the pharmaceutical industry: a systematic review. PLoS Med. 2011;8(5):e1001037.PubMedCrossRef
14.
go back to reference Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA. 2000;283(3):373–380.PubMedCrossRef Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA. 2000;283(3):373–380.PubMedCrossRef
15.
go back to reference Bowman MA, Pearle DL. Changes in drug prescribing patterns related to commercial company funding of continuing medical education. J Contin Educ Health Prof. 1988;8:13–20.PubMedCrossRef Bowman MA, Pearle DL. Changes in drug prescribing patterns related to commercial company funding of continuing medical education. J Contin Educ Health Prof. 1988;8:13–20.PubMedCrossRef
16.
go back to reference Sondergaard J, Vach K, Kragstrup J, Andersen M. Impact of pharmaceutical representative visits on GPs’ drug preferences. Fam Pract. 2009;26:204–209.PubMedCrossRef Sondergaard J, Vach K, Kragstrup J, Andersen M. Impact of pharmaceutical representative visits on GPs’ drug preferences. Fam Pract. 2009;26:204–209.PubMedCrossRef
17.
go back to reference Institute of Medicine. Conflict of interest in medical research, education, and practice. Washington, D.C.: National Academies Press; 2009. Institute of Medicine. Conflict of interest in medical research, education, and practice. Washington, D.C.: National Academies Press; 2009.
22.
go back to reference Fugh-Berman A, Brown SR, Trippett R, Bell AM, Clark P, Fleg A, Siwek J. Closing the door on pharma? A national survey of family medicine residencies regarding industry interactions. Acad Med. 2011;86(5):649–654.PubMedCrossRef Fugh-Berman A, Brown SR, Trippett R, Bell AM, Clark P, Fleg A, Siwek J. Closing the door on pharma? A national survey of family medicine residencies regarding industry interactions. Acad Med. 2011;86(5):649–654.PubMedCrossRef
23.
go back to reference Kao AC, Braddock C 3rd, Clay M, Elliott D, Epstein SK, Filstead W, Hotze T, May W, Reenan J. Effect of educational interventions and medical school policies on medical students’ attitudes toward pharmaceutical marketing practices: a multi-institutional study. Acad Med. 2011;86(11):1454–1462.PubMedCrossRef Kao AC, Braddock C 3rd, Clay M, Elliott D, Epstein SK, Filstead W, Hotze T, May W, Reenan J. Effect of educational interventions and medical school policies on medical students’ attitudes toward pharmaceutical marketing practices: a multi-institutional study. Acad Med. 2011;86(11):1454–1462.PubMedCrossRef
24.
go back to reference Weissman JS, Betancourt J, Campbell EG, Park ER, Kim M, Clarridge B, Blumenthal D, Lee KC, Maina AW. Resident physicians' preparedness to provide cross-cultural care. JAMA. 2005;294(9):1058–1067.PubMedCrossRef Weissman JS, Betancourt J, Campbell EG, Park ER, Kim M, Clarridge B, Blumenthal D, Lee KC, Maina AW. Resident physicians' preparedness to provide cross-cultural care. JAMA. 2005;294(9):1058–1067.PubMedCrossRef
27.
go back to reference Johnson TP, Wislar JS. Response rates and nonresponse errors in surveys. JAMA. 2012;307(17):1805–1806.PubMedCrossRef Johnson TP, Wislar JS. Response rates and nonresponse errors in surveys. JAMA. 2012;307(17):1805–1806.PubMedCrossRef
28.
go back to reference Kesselheim AS, Mello MM, Studdert DM. Strategies and practices in off-label marketing of pharmaceuticals: a retrospective analysis of whistleblower complaints. PLoS Med. 2011;8(4):e1000431.PubMedCrossRef Kesselheim AS, Mello MM, Studdert DM. Strategies and practices in off-label marketing of pharmaceuticals: a retrospective analysis of whistleblower complaints. PLoS Med. 2011;8(4):e1000431.PubMedCrossRef
29.
go back to reference Mullan F, Chen C, Petterson S, Kolsky G, Spagnola M. The social mission of medical education: ranking the schools. Ann Intern Med. 2010;152(12):804–811.PubMedCrossRef Mullan F, Chen C, Petterson S, Kolsky G, Spagnola M. The social mission of medical education: ranking the schools. Ann Intern Med. 2010;152(12):804–811.PubMedCrossRef
30.
go back to reference Chimonas S, Brennan TA, Rothman DJ. Physicians and drug representatives: exploring the dynamics of the relationship. J Gen Intern Med. 2007;22(2):184–190.PubMedCrossRef Chimonas S, Brennan TA, Rothman DJ. Physicians and drug representatives: exploring the dynamics of the relationship. J Gen Intern Med. 2007;22(2):184–190.PubMedCrossRef
31.
go back to reference Chren M-M, Landefeld CS. Physicians’ behavior and their interactions with drug companies: a controlled study of physicians who requested additions to a hospital drug formulary. JAMA. 1994;271:684–689.PubMedCrossRef Chren M-M, Landefeld CS. Physicians’ behavior and their interactions with drug companies: a controlled study of physicians who requested additions to a hospital drug formulary. JAMA. 1994;271:684–689.PubMedCrossRef
32.
go back to reference Manchanda P, Honka E. The effects and role of direct-to-physician marketing in the pharmaceutical industry: an integrative review. Yale J Health Policy Law Ethics. 2005;5:785–812.PubMed Manchanda P, Honka E. The effects and role of direct-to-physician marketing in the pharmaceutical industry: an integrative review. Yale J Health Policy Law Ethics. 2005;5:785–812.PubMed
33.
go back to reference Avorn J, Chen M, Hartley R. Scientific versus commercial sources of influence on the prescribing behavior of physicians. Am J Med. 1982;73(1):4–8.PubMedCrossRef Avorn J, Chen M, Hartley R. Scientific versus commercial sources of influence on the prescribing behavior of physicians. Am J Med. 1982;73(1):4–8.PubMedCrossRef
34.
go back to reference Agrawal S, Saluja I, Kaczorowski J. A prospective before-and-after trial of an educational intervention about pharmaceutical marketing. Acad Med. 2004;79:1046–1050.PubMedCrossRef Agrawal S, Saluja I, Kaczorowski J. A prospective before-and-after trial of an educational intervention about pharmaceutical marketing. Acad Med. 2004;79:1046–1050.PubMedCrossRef
35.
go back to reference Austad KE, Kesselheim AS. Conflict of interest disclosure in early medical education: should medical students stay in the dark? JAMA. 2011;306:991–992.PubMedCrossRef Austad KE, Kesselheim AS. Conflict of interest disclosure in early medical education: should medical students stay in the dark? JAMA. 2011;306:991–992.PubMedCrossRef
36.
go back to reference Asch DA, Jedrziewski MK, Christakis NA. Response rates to mail surveys published in medical journals. J Clin Epidemiol. 1997;50(10):1129–1136.PubMedCrossRef Asch DA, Jedrziewski MK, Christakis NA. Response rates to mail surveys published in medical journals. J Clin Epidemiol. 1997;50(10):1129–1136.PubMedCrossRef
Metadata
Title
Changing Interactions Between Physician Trainees and the Pharmaceutical Industry: A National Survey
Authors
Kirsten E. Austad, BS
Jerry Avorn, MD
Jessica M. Franklin, PhD
Mary K. Kowal, BA
Eric G. Campbell, PhD
Aaron S. Kesselheim, MD, JD, MPH
Publication date
01-08-2013
Publisher
Springer US
Published in
Journal of General Internal Medicine / Issue 8/2013
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-013-2361-0

Other articles of this Issue 8/2013

Journal of General Internal Medicine 8/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.